Rush University System for Health has procured the Epione platform from Quantum Surgical, a robotic-assisted technology designed for interventional radiologists.
This system facilitates the accurate removal of tumours within the abdomen, presenting a less invasive solution for patients harbouring smaller tumours.
The Epione platform enhances the accuracy of tumour ablation procedures by supporting physicians in planning optimal targeting and monitoring the patient's real-time position.
The robotic arm accurately aligns the doctor's tools, and enables instant verification of the tumour's successful removal.
Rush vascular and interventional radiology director Bulent Arslan said: “Rush’s interventional radiology programme is one of the best programmes in the country, excelling in clinical interventional care, education with one of the largest and most sought-after residency programmes, and robust research activities with multiple ongoing clinical trials.
“Robotic systems have been in surgical care for many years and now are available for the interventional care of patients. We treat complex lesions throughout the body with ablative therapies, but it is not always easy to reach our targets, and there is some risk involved in the process.
“Using Epione, we will be able to reach most locations with computerised guidance using patients’ existing CT or MRI images relatively easily and with less risk. This is an evolution in cancer patient care, and we are excited to be the first in the Chicago area to offer it.”
Although surgical intervention might be feasible for certain individuals, it typically incurs greater expenses and extended durations of hospitalisation.
Epione provides a less intrusive substitute, permitting patients to be discharged on the day of the procedure with negligible convalescence necessitated.
Quantum Surgical CEO and co-founder Bertin Nahum said: “We are thrilled to celebrate this milestone as Quantum Surgical’s Epione platform arrives in the Midwest.
“We are excited to collaborate with the esteemed team at Rush University System for Health, as our mission is to ensure that as many cancer patients as possible can benefit from this minimally invasive technology.”
